Caremo Honored as One of the "Top 50 Pharmaceutical R&D Companies for 2023-2024"

From November 4 to 6, the 3rd Taishan Pharmaceutical Forum and the "2023-2024 Pharmaceutical Industry Information Conference" were successfully held in Jinan, Shandong Province. During the event, Nanjing Caremo Biomedical Co., Ltd. (referred to as "Caremo") was recognized as one of the "Top 50 Pharmaceutical R&D Companies for 2023-2024" in China’s pharmaceutical industry.

Centered on the theme "Integrated Industry, Expanded Platforms, Deep Collaboration, Shared Growth," the forum brought together leading experts and stakeholders to explore cutting-edge technologies, strategic directions, and collaborative opportunities for the future of pharmaceutical and healthcare innovation. The "Top 50 Pharmaceutical R&D Companies" list was compiled through a rigorous evaluation of corporate operational performance, team expertise, innovation capabilities, and R&D achievements. Awardees represent industry leaders in standardization, digitalization, and scalability across the full spectrum of pharmaceutical services.

Caremo’s inclusion in this prestigious ranking underscores its technical prowess, professional excellence, and innovative impact. Guided by its corporate mission—“Born for Health, Empowered for Innovation”—the company leverages core technologies to bridge the entire development lifecycle of “innovative drugs + generic drugs.” Through its dual-drive strategy of “R&D + industrialization”—anchored in research as the foundation and commercialization as the goal—Caremo delivers tailored R&D and industrial solutions tailored to the diverse needs of global clients.